Structural basis for how sMAC is packaged for clearance

Anaïs Menny^{1#}, Marie V. Lukassen^{2,3#}, Emma C. Couves¹, Vojtech Franc^{2,3}, Albert J.R. Heck^{2,3}, Doryen Bubeck^{1*}

¹ Department of Life Sciences, Sir Ernst Chain Building, Imperial College London, London SW7 2AZ, United Kingdom

² Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands

³ Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands

Equal contribution

*Correspondence to: d.bubeck@imperial.ac.uk

Unregulated complement activation causes inflammatory and immunological pathologies with consequences for human disease. To prevent bystander damage during an immune response, extracellular chaperones (clusterin and vitronectin) capture and clear soluble precursors to the membrane attack complex (sMAC). However, how these chaperones block further polymerization of MAC and prevent the complex from binding target membranes remains unclear. Here, we address that question by combining cryo electron microscopy (cryoEM) and cross-linking mass spectrometry (XL-MS) to solve the structure of sMAC. Together our data reveal how clusterin recognizes and inhibits polymerizing complement proteins by

binding a negatively charged surface of sMAC. Furthermore, we show that the pore-forming C9 protein is trapped in an intermediate conformation whereby only one of its two transmembrane β -hairpins has unfurled. This structure provides molecular details for immune pore formation and helps explain a complement control mechanism that has potential implications for how cell clearance pathways mediate immune homeostasis.

Introduction

The complement membrane attack complex (MAC) is an immune pore that directly kills pathogens and causes human disease if left unchecked. One of the first lines of defence against Gram-negative bacteria ¹, MAC is a potent weapon of the innate immune system that can rupture lipid bilayers of any composition. Therefore, MAC is highly regulated on human cells to prevent damage ^{2,3}. An inhibitory protein blocks MAC assembly and pore formation that occurs directly on the plasma membrane of human cells ⁴. However, complexes that have improperly assembled on bacterial target membranes are shed into plasma and are capable of lysing red blood cells ⁵. When released from complement-opsonized pathogens, these complexes can also deposit on nearby macrophages and initiate a cascade of inflammatory responses causing bystander damage ⁶. Therefore, understanding how MAC is controlled is essential for our ability to tune the activity of a potent innate immune effector and prevent human disease.

Soluble MAC (sMAC) is an immune activation complex that is formed from MAC assembly precursors released into plasma and scavenged by blood-based chaperones. While in

healthy individuals sMAC exists in trace amounts, these levels are dramatically elevated during an immune response, providing a biomarker for infectious and autoimmune disease ^{7,8}, transplant ^{9,10} and trauma ¹¹. sMAC, also known as sC5b9, is composed of the complement proteins C5b, C6, C7, C8 and C9 together with the extracellular regulatory proteins, clusterin and vitronectin ^{12,13}. Derived from MAC precursors, sMAC is a model system for understanding structural transitions underpinning MAC assembly. In both sMAC and MAC, complement proteins associate through their pore-forming membrane attack complex perforin (MACPF) domain ^{14,15}. Structures of MAC ^{15,16} and soluble C9 ¹⁷ show that complement proteins undergo substantial conformational rearrangements to enable pore formation. While these studies have contributed to our understanding of the final pore, little is known of how regulators trap transition states and clear activation byproducts.

Clusterin (also called apolipoprotein J) is a chaperone that broadly protects against pathogenic aggregation of proteins. Upregulated in response to cellular stress ¹⁸, clusterin recognizes a variety of cellular targets and trafficks cargo for disposal. Within sMAC, clusterin binds fluid-phase oligomeric complement complexes generated during an immune response ¹² and inhibits polymerization of C9 ¹⁹. The chaperone also directly associates with amyloid-beta fibrils formed from the polymerizing A β peptide and prevents peptide aggregation ^{20,21}. Indeed, mutation of the gene encoding clusterin, *CLU*, is one of the greatest genetic risk factors for late-onset Alzheimer's disease ²². Although the roles of clusterin in protein quality control and clearance pathways are well established, the

molecular mechanism by which clusterin recognizes and trafficks cargo for degradation remains unclear.

To understand how fluid-phase chaperones trap and clear MAC assembly intermediates, we combined cryo electron microscopy (cryoEM) and cross-linking mass spectrometry (XL-MS) to solve the structure of sMAC. We find that sMAC is a heterogeneous complex in which the pore-forming MACPF domain of C9 is caught in a transition state. We also provide a molecular basis for how C7 may activate C5b to propagate MAC assembly. Finally, we discover that clusterin can bridge MAC proteins through electrostatic interactions and obstruct the polymerizing face of C9. Taken together, these data provide a structural framework for understanding pore formation and the molecular details for a complement control mechanism.

Results

sMAC is a heterogeneous multi-protein complex

Complement activation produces soluble protein assemblies that are cleared by chaperones in blood plasma. To understand how these immune activation macromolecules are trapped and shuttled for removal, we used cryoEM to visualize sMAC (Fig. 1 and Supplementary Fig. 1). In accordance with lower resolution studies¹⁴, we find that C5b supports the assembly of complement proteins (C6, C7, C8 and C9) into an arc-like arrangement of MACPF domains. We discover that sMAC extends 260 Å in length with clear density for extended β-hairpins of MACPF domains. Similar to MAC¹⁵, sMAC contains a single copy of the complement proteins C5b, C6, C7 and C8 while the

stoichiometry of C9 varied between one to three copies (Supplementary Fig. 1). Using 3D classification of cryoEM images, we generated reconstructions for complexes with either one, two or three copies of C9 to a resolution of 3.8 Å, 3.3 Å and 3.5 Å, respectively (Fig. 1a, 1b and Supplementary Fig. 1). Anisotropy in 1C9-sMAC reconstruction prevented further modeling of this complex; however, cryoEM density maps for the 2- and 3-C9 sMAC complexes were sufficient to build a near-complete atomic model for all complement proteins (Fig. 1a, 1b, Supplementary Fig. 2 and Supplementary Table 1). Density for clusterin and vitronectin were not well resolved in these initial maps, consistent with the flexible nature of these chaperones.

To confirm the composition and structure of proteins in sMAC, we performed label-free quantitative proteomics and XL-MS on sMAC. Our proteomics analysis confirmed the presence of all complement proteins (C5b, C6, C7, C8 and C9), with C9 twice as abundant as the others (Supplementary Fig. 3). In agreement with sedimentation centrifugation measurements¹³, our analyses also revealed the presence of clusterin and vitronectin with abundances 2-6 times higher than that of C5b, C6, C7 and C8 (Supplementary Fig. 3). All other proteins detected in the sMAC sample were an order of magnitude less abundant. In the XL-MS data we observed a number of intra- and inter-protein cross-links between complement proteins, with 88% fitting the distance restraints of the atomic models derived from our sMAC reconstructions (Supplementary Fig. 4 and Source data file). Furthermore, we observed several inter-links between complement proteins, vitronectin and clusterin, confirming their presence in the complex (Fig. 1c, Supplementary Fig. 3 and Source data file). Mass photometry of sMAC showed a handful

of co-occurring multi-protein complexes with distinct masses between 971 and 1374 kDa (Supplementary Fig. 3). After subtracting masses corresponding to the core complement complex (C5b6, C7, C8) together with one, two or three C9 molecules, we are left with excess masses of minimally ~241 and maximally ~777 kDa. As the molecular weights of secreted clusterin and vitronectin are ~80 kDa and ~75 kDa, respectively, we attribute this excess to multiple copies of both these chaperones.

We next sought to verify that purified sMAC, used for cryoEM and XL-MS, reflects the complex formed during an immune response. Specifically, we used bacteria to activate complement directly in serum and compared these complexes with those found in non-activated serum. We separated serum components by size exclusion chromatography (SEC) and analyzed individual fractions by liquid chromatography-tandem mass spectrometry (LC-MS/MS). By profiling of sMAC components in serum, we found that in non-activated serum these components elute later in the SEC profile, corresponding to monomeric or low molecular weight complexes (Fig. 1d). Upon activation, the profiles of all sMAC components largely co-elute and are dramatically shifted to fractions that correspond to higher mass ranges. In agreement with our proteomic and cryoEM analysis, the most abundant complexes correlate with a ratio of 2-3 C9 molecules to the average abundance of the core complex (C5b6, C7, C8) and with clusterin as the main binding-chaperone. Together these data confirm that sMAC is a heterogeneous assembly comprising a single copy of a conserved core complex (C5b6, C7 and C8) together with multiple copies of C9, clusterin and vitronectin in a mixture of stoichiometries.

Clusterin bridges complement proteins through electrostatic interactions

With the high abundance of clusterin and vitronectin in sMAC, we next sought to identify their location in the complex. Given the extensive cross-links observed between the chaperones and C9 (Fig. 1c, Supplementary Fig. 3, and Source data file), we subtracted density corresponding to proteins C5b6, C7 and C8 from the raw EM images and focused our refinement on the C9 component of the complex (Fig. 2a). In doing so, we resolve a 10nm stretch of density that bridges the negatively charged crown of C9 lipoprotein receptor class A (LDL) domains. This density caps a similarly negatively charged polymerizing face of the C9 MACPF (Fig. 2c and d). We also observe a second belt of density below the C9 epidermal growth factor (EGF) domains (Fig. 2c). Locally sharpened maps indicate tubular densities consistent with alpha helices; however, this region remains highly flexible and we were unable to model it based on our cryoEM maps.

We next considered the possible identity of this extra density. All complement proteins within sMAC are accounted for within the map; therefore, we conclude that this density is composed of plasma-based chaperones. Based on our XL-MS data, both clusterin and vitronectin interact with C9 (Fig. 1c and Supplementary Fig. 3). We then plotted the location of complement protein residues in our 3C9-sMAC model that uniquely cross-link to each chaperone (Supplementary Fig. 3). We find that cross-links between clusterin and C9 congregate around the two extra densities observed in our focus-refined map (Fig. 2c). By contrast, unique cross-links between vitronectin and C9 lie on the back face of the map (Supplementary Fig. 3). These residues are not resolved in the final C9 of the 3C9-

sMAC reconstruction; therefore, it is also possible that they reflect cross-links to the mobile terminal C9 in other sMAC stoichiometries. Additionally, we find that the number of cross-links between vitronectin and C9 are identified about 3.5 times less than those observed to clusterin. As the cross-linkers used in these experiments bridge charged residues (Lys-Lys or Asp/Glu-Lys), these data could indicate that vitronectin binds to a hydrophobic region of C9, which is in agreement with immuno-gold labeling experiments that map the vitronectin bind-site to the MACPF hydrophobic hairpins²³. While we observe some density for this region in other focused refinements (Supplementary Fig. 1), the area is not well ordered in our maps. Taken together, our data demonstrate that clusterin likely occupies some or all of the extra density present above the C9 LDL domains in our focus-refined map.

Clusterin is a highly glycosylated²⁴, disulfide-linked heterodimer²⁵ whose tertiary structure remains unknown. Using trRosetta²⁶, which combines co-evolutionary data with deep learning, we generated a panel of possible clusterin structural models (Supplementary Fig. 5). All models contained a common helical core component with structural similarity to the MAC inhibitor CspA from *Borrelia burgdoferi*^{27,28} (Supplementary Fig. 5). The clusterin core model extends 10nm in length and is consistent with the density in our focus-refined map (Fig. 2a and b). To further optimize our model, we then applied known disulfide-bond restraints for clusterin using Modeller²⁹. We next assessed the validity of our model by plotting the unique intra-molecular clusterin cross-links observed in our XL-MS experiments (Fig. 2b). In doing so, we verify that 92% of clusterin cross-links satisfy the distance restraints of our model

(Supplementary Fig. 5 and Source Data file). Our analyses show that clusterin contains an extended helical domain capped by a helical bundle, whose arrangement is defined by five disulfide bonds (Fig. 2b). The electrostatic surface potential of the clusterin core model reveals a contiguous patch of positive charge, complementary to the surface charge of C9 at the interface with clusterin in sMAC (Fig. 2d). Beyond this core, we find that clusterin makes additional cross-links with a range of complement proteins distal from C9 (Supplementary Fig. 3). Indeed, the ensemble of models produced by trRosetta reveals long extended domains that flexibly hinge from the core (Supplementary Fig. 5). Altogether, our data are consistent with a model that clusterin is a highly flexible protein, whose core domain engages cargo through electrostatic interactions to block propagation of polymerizing proteins.

C-terminal domains of C7 position the C345C domain of C5b

Previous structural studies of MAC were limited in resolution due to the flexibility and varied curvature of the complex¹⁶. In particular, the C-terminal domains of C7 and their interaction with C5b remained unmodeled. As a result, it remained unclear how C7 activates C5b6 to propagate MAC assembly. To understand how the C7 C-terminal domains prime the complex for C8 recruitment, we sought to improve the resolution of the map in this area. Density for C5b was best resolved in our 2C9 sMAC map; therefore, we used this map for subsequent refinement steps in which density corresponding to the MACPF arc was subtracted (Fig. 3a). By focusing our alignment on C5b, we calculated a map with a resolution of 3.6 Å which enabled us to build a near complete atomic model for sMAC incorporated C7. By contrast to the extensive interaction interface between the

C6 complement control protein (CCP) domains and C5b, we find that the binding site of C5b and the C-terminal CCPs of C7 is punctuated by three specific contact points (Fig. 3b). In our map, we observe clear side-chain density for ionic interactions between C7:Asn₅₇₂/Arg₅₉₀ and Cb5:Gln₇₃, which appears to stabilize the position of the first C7 CCP. We also observe unambiguous density for C5b:Trp₇₆₁ that wedges into a hydrophobic groove connecting the two CCPs and likely impacts the orientation of these domains. Stabilized by a glycan on C5b (Asn₉₈₃), a flexible linker connects the C7 CCPs and the final two factor I-like membrane attack complex (FIM) domains. Our data show that the first FIM domain is responsible for binding the C345C domain of C5b (Fig. 3a and d). Superposition of C5b from the soluble C5b6¹⁴ and its conformation in sMAC shows that this domain undergoes the largest movement during MAC assembly (Fig. 3d). Interestingly, we find that the orientation of the C345C domain of C5b in our model overlays with its position in a structural homologue, C3b, when bound to Factor B and properdin in an activated conformation³⁰ (Fig. 3e). In addition, we find that the Macroglobulin (MG) 4 and MG5 domains of C5b also move to accommodate C8 allowing a network of salt bridges between the loops of the C5b MG scaffold and the LDL domain of C8 β (Fig. 3c). We therefore propose that the C-terminal domains of C7 may position the C5b C345C domain in an activated conformation that enables the recruitment of complement proteins to the MG scaffold.

Structural transitions of MACPF domains

The MACPF domain of complement proteins undergo dramatic structural rearrangements during pore formation. Structures of soluble^{17,31-33} and membrane inserted forms¹⁶ of

complement proteins have shown that two helical bundles within the MACPF (TMH1, TMH2) unfurl to form transmembrane β -hairpins. To understand how the helix-to-hairpin transition of MACPF residues is mediated, we sought to model a conformation of C9 for which MAC assembly is stalled. As the density for C9 is best resolved in the 2C9-sMAC complex, we used this map for subsequent analyses. We next subtracted density for C5b6, C7 and C8 from the raw images. By then focusing refinement on the remaining C9, we were able to generate a map at 3.3 Å resolution in which density for both copies of C9 were clearly resolved (Fig. 4 and Supplementary Fig. 1).

We discover that within sMAC, C9 adopts two distinct conformations. Upon binding C8, the first C9 molecule undergoes a complete transition in which both TMH1 and TMH2 are extended, and CH3 is in a position analogous to MAC (Supplementary Fig. 6). By contrast, only one helical bundle (TMH1) has unfurled in the terminal C9 conformation. There is no density for the extended hairpins of TMH2; instead, these residues adopt a conformation similar to that of soluble C9 (Fig. 4a, b). To validate our model for the terminal C9 conformation, we used the XL-MS data and mapped intramolecular C9 cross-links. We identify four cross-links within TMH2 that satisfy all the distance restraints when plotted on the stalled conformation (9 Å, 14 Å, 17 Å, 20 Å) (Fig. 4e). Two are over-length when mapped onto the MAC conformation of C9 (17 Å, 28 Å, 32 Å, 59 Å), further supporting that C9 transmembrane hairpins unfurl sequentially. In the stalled C9, CH3 follows the movement of the central β -sheet of the MACPF domain, which aligns with the preceding monomer (Fig. 4b). In doing so, the helical TMH2 bundle swings out and positions the sidechain of Arg₃₄₈ proximal to a glycan (NAG-Asn₃₉₄) on the β -strand of the

penultimate C9 molecule (Fig. 4c). We hypothesize that this interaction may play a role in stabilizing an intermediate state in which the preceding monomer templates TMH1 β -strands and correctly positions TMH2 for sequential unfurling (Fig. 4f).

We next considered how this stalled conformation of C9 might help us understand disease-related variants. Several point mutations within the C9 MACPF are associated with Age-related Macular Degeneration (AMD)³⁴. In particular, substitution of Pro¹⁴⁶ (P146S) within a loop of C9 directly influences polymerization of C9. Unlike its position in the MAC, we find that this loop flips outward in the stalled conformation, sterically blocking subsequent C9 incorporation (Fig. 4d). Substitution of proline at this position may impact the ability of this loop to serve as a checkpoint for polymerization. Taken together, our sMAC model provides a structural timeline in which the sequential extension of transmembrane β -hairpins may be regulated by the preceding monomer and a proline latch on the polymerizing MACPF interface (Fig. 4f).

Discussion

In sMAC, fluid-phase chaperones prevent bystander damage by trapping MACPF-containing complement complexes. As such, sMAC represents an important model system to probe structural transitions of pore-forming proteins. In addition to MAC, two other human immune pores (perforin-1 and MPEP-1) rupture membranes using MACPF domains (Supplementary Fig. 6). While structures are available for both soluble and membrane-inserted states of these complexes³⁵⁻³⁷, mechanistic details governing the transition between the two conformations have been more challenging to study.

Here we capture a stalled conformation of C9 that allows us to define a structural pathway for MACPF pore-formation (Fig. 4f). As soluble monomers integrate into a growing pore, the central kinked β -sheet of the MACPF straightens to align with the preceding monomer. Our data show how two helical bundles (CH3 and TMH2) rotate to stabilize a transition state, in which a basic residue on TMH2 interacts with a glycan on the β -strands of a preceding monomer. We hypothesize that this interaction may play a role in correctly positioning TMH2 as the first β -hairpin (TMH1) geometry is templated by the strands of the preceding monomer. Indeed, removal of N-linked glycans from C9 resulted in MACs with distorted β -barrels¹⁶. The pore is then propagated by the sequential insertion of the second β -hairpin, TMH2. We note that within the pore conformation, MPEG-1 contains a glycan on the leading edge of TMH2³⁷, analogous to C9. Remarkably, superposition of a soluble conformation of MPEG-1 positions a basic residue proximal to TMH2 glycan of the preceding monomer (Supplementary Fig. 6). We therefore propose that glycans may play a role in stabilizing transition states of MACPF pore-formation.

In addition to understanding immune pore-formation, our combined cryoEM and XL-MS data provide a molecular basis for how clusterin binds cargo. Based on results presented here, we show that clusterin is a predominantly helical protein that binds to a negatively charged surface on sMAC. Specifically, we find that clusterin caps the polymerizing face of the leading MACPF domain, thus providing a mechanism for how clusterin prevents C9 polymerization³⁸. We also define a binding site for clusterin that spans LDL domains of multiple complement proteins, in agreement with studies that suggest clusterin binds a

structural motif common to C7, C8 α and C9³⁸. Density for clusterin at this site is the most well resolved in the 3C9-sMAC maps; therefore, the interaction is likely secured through repeated contacts across oligomers. Clusterin also binds oligomeric amyloid-beta fibrils through the same interaction interface as sMAC³⁹. As clusterin inhibits amyloid-beta aggregation *in vitro*^{40,41}, this may serve as a general mechanism for how clusterin blocks polymerization of potentially pathogenic proteins. In addition to the LDL binding site, we observe a second stretch of density below the EGF domains of C9. This density also maps to a clusterin binding-site supported by our XL-MS data. Indeed, our MS data reveal that multiple copies of clusterin are present in sMAC. While the role of this second binding site in regulating pore formation remains unclear, it may be important in linking cargo with an endocytic receptor for clearance⁴². Clusterin is rapidly emerging as a key player at the crossways between clearance pathways and immune homeostasis⁴³. Our structure of sMAC shows how clusterin can bind polymerizing cargo and opens new lines of investigation into the role of clusterin in immunobiology.

In summary, we have solved multiple structures of complement activation macromolecules by combining cryoEM and mass spectrometry. These structures underpin a complement control pathway that prevents bystander damage during an immune response. Our structural analyses show how chaperones trap pore-forming intermediates and bind oligomeric proteins to prevent further polymerization, which may also be relevant for controlling pathogenic aggregation of amyloids. Finally, we anticipate that our structural findings will provide mechanistic insight into transition states of immune pores.

326

327 **Materials and methods**

328 **CryoEM sample and grid preparation**

329 To prepare cryoEM grids, sMAC (Complement Technologies) was diluted to 0.065 mg/ml
 330 in 120 mM NaCl, 10 mM Hepes pH7.4 and used for freezing within the hour. 4 μ l were
 331 deposited on glow-discharged gold grids with a lacey carbon film (Agar Scientific). After
 332 a 10 sec incubation at room temperature and 95% humidity, grids were blotted and flash
 333 frozen in liquid ethane using a Vitrobot Mark III (Thermo Fisher Scientific). CryoEM
 334 conditions were screened using a Tecnai T12 (Thermo Fisher Scientific) operated at
 335 120 kV. Two data sets were collected on 300 kV Titan Krios microscopes (Thermo Fisher
 336 Scientific) equipped with K2 Quantum direct electron detectors (Gatan) operated in
 337 counting mode at a magnification of 130k, corresponding to a calibrated pixel size of 1.047
 338 Å and 1.048 Å for each dataset, respectively. The first data set was collected at 0 degree
 339 tilt and consisted of 11,107 image stacks taken over a defocus range of -1.1 to -2.3 μ m
 340 in 0.3 μ m steps. The total exposure time was 8 seconds which included 40 frames and
 341 resulted in an accumulated dose of 40 electrons per Å². As initial processing of the first
 342 dataset showed the particles adopted a favored orientation, we used the cryoEF software
 343 ⁴⁴ to estimate the appropriate tilt angle for data collection and acquisition of missing views.
 344 The second data set was collected at a 37 degree tilt and consisted of 2,596 image stacks
 345 over a defocus range of -1.1 to -2.1 μ m. Movie stacks were collected with similar
 346 conditions as dataset-1. A summary of the imaging conditions is presented in
 347 Supplementary Table 1.

348 **Image processing**

Electron micrograph movie frames were aligned with a Relion-3.1⁴⁵ implementation of MotionCorr. CTF parameters were estimated using CTFFIND4-1⁴⁶. The datasets were manually curated to remove movies with substantial drift and crystalline ice. For dataset-1, a small subset of micrographs across the whole defocus range were randomly selected for manual picking in Relion. Following 2D classification, classes with diverse orientations were used for Autopick of the entire dataset. Due to the use of a lacey carbon film grid, a large portion of micrographs were acquired over a steep ice gradient and with visible carbon edges. Relion Autopick performed best to avoid over-picking on carbon when calibrated to pick in thinner ice areas. To complement the particle stacks, crYOLO⁴⁷ was used in parallel and specifically trained to pick in thicker ice areas. Particles were extracted at 4.188 Å/px (bin by 4) and subjected to iterative 2D classification to remove ice contamination, carbon edges and broken particles. An initial model was generated in Relion which was strongly low-pass filtered to 60 Å resolution and used as a starting model for 3D auto-refinement. The initial refinement with 595,890 particles revealed strong particle distribution anisotropy. To improve the diversity of particle orientations, projections of low occurrence views were generated from the initial reconstruction and used as templates for re-picking the micrographs in Relion. In parallel, the reweight_particle_stack.py script (available on the Leschziner lab Github) was iteratively used to randomly select and remove particles from the over-represented orientation, followed by 3D auto-refinements of the remaining particles. Duplicated particles identified within a distance threshold of 10 nm were removed at each data merging step resulting in a final 389,625 particles in dataset-1. For dataset-2, manual picking of a small subset of micrographs followed by 2D classification at 4.192 Å/px (bin by 4) was first done and

372 five classes were then used for autopicking of all the micrographs in Relion. The picks
 373 were cleaned in iterative 2D classifications, resulting in a final 83,376 particles. Unbinned
 374 particles from dataset-1 and -2 were then merged for a 3D auto-refinement yielding a
 375 consensus map at 3.8 Å with 473,001 particles. Low map quality in the C9 arc suggested
 376 heterogeneity in this area. The aligned particles were thus subtracted to only keep the C9
 377 arc, followed by 3D classification without refinement (bin 4, T=20, 10 classes) which
 378 identified three sMAC stoichiometries, with 1 C9 (20.6 %), 2 C9 (29.5 %) or 3 C9 (17.9 %
 379 of particles). Particle stacks were reverted to the original images and each class was 3D
 380 auto-refined individually, followed by Bayesian polishing and multiple rounds of per-
 381 particle CTF refinements ⁴⁸ (Supplementary Fig. 1) to generate the final reconstructions
 382 for 1C9-sMAC (EMD-12649), 2C9-sMAC (EMD-12651) and 3C9-sMAC (EMD-12650)
 383 (resolutions 3.8 Å, 3.3 Å and 3.5 Å respectively). Further heterogeneity analysis via multi-
 384 body refinement of sMAC revealed flexibility within the complex. To better resolve the C-
 385 terminal domains of C5b and C7, density subtraction of the MACPF arc was done on the
 386 best-resolved 2C9-sMAC map. The subtracted particles were then aligned in a masked
 387 3D auto-refinement to generate a reconstruction at 3.6 Å (EMD-12648). Similarly, the
 388 2C9-sMAC particles were density subtracted only keeping the signal from the terminal 2
 389 C9s. The 2C9 subtracted particle set was further subjected to 2D classification to remove
 390 any remaining heterogeneity in the number of C9s. A final 96,118 particles were selected
 391 for a masked 3D auto-refinement resulting in a 3.3 Å reconstruction (EMD-12647). The
 392 3C9-sMAC reconstruction contained weak density above the C9 arc suggesting poor
 393 alignment of particles in this area. To better resolve this area, density was subtracted from
 394 the raw particles using a generous mask extending above the density and containing the

three terminal C9s, followed by 3D auto-refinement. A second round of subtraction was done on the newly aligned particles to only keep the MACPF region and the newly resolved density above it. A final masked 3D auto-refinement generated a reconstruction at 3.8 Å (EMD-12646). Resolutions of maps were determined using the masking-effect corrected Fourier Shell Correlation (FSC) as implemented in Relion post-processing.

Model building and refinement

Models were built and refined into locally sharpened maps generated by DeepEMhancer⁴⁹. To create initial starting models, complement proteins (C5b, C6, C7, and C8) from MAC (PDB ID: 6H04)¹⁶ were augmented or substituted with higher resolution structures for individual domains. Specifically, the TED, MG8 and C345C domains of C5b and C6 CCP domains were derived from the C5b6 crystal structure (PDB ID: 4A5W)¹⁴; C7-FIM domains were included from the NMR structure (PDB ID: 2WCY)⁵⁰. As we observe two conformations of C9 in sMAC, we created two unique starting models (C9₁ and C9₂). C9₁ was derived from its MAC conformation (trimmed to remove unresolved TMH2 residues). C9₂ was generated by replacing TMH2 residues from the MAC conformation of C9 (PDB ID: 6H03)¹⁶ with TMH2 helices from the soluble murine C9 structure (PDB ID: 6CXO)¹⁷. Amino acids from the murine model were subsequently changed to the human sequence in Coot⁵¹. All missing amino acids in C9 were manually built in areas where density was present. Flexible regions of TMH1 hairpins were removed to match the density. The terminal C9 EGF domain was also removed from the model as density for this region was not well defined. Where merited by the EM density, missing loops and individual amino acids were manually built in Coot. Where appropriate, known calcium ions were also added in Coot. All models were refined into the EM densities using ISOLDE⁵² as a built-

in module in ChimeraX⁵³, with secondary structure geometries restraints and ligand position restraints applied. All reasonable disulfides were formed in ISOLDE to stabilize the protein chains during refinements.

We used density subtracted focus-refined maps to generate more accurate models for individual subregions. To generate the model for the interaction interface between C5b and C7, individual domains derived from higher resolution structures (C5b:C345C, C5b:MG8, C6:CCPs and C7:FIMs) were rigid body fitted into the density subtracted C5b-focus refined 2C9-sMAC (EMD-12648) using ChimeraX. Models were merged with the rest of C5b, C6 and C7 in Coot and further refined in ISOLDE where adaptive distance restraints were kept active for C5b:C345C and two C7:FIM domains. The density subtracted C9-focus refined 2C9-sMAC (EMD-12647) was used to refine atomic models for the two C9 conformations using ISOLDE.

Following building and refinement in the density subtracted maps, final composite models were created for both 2C9-sMAC (PDB ID: 7NYD) and 3C9-sMAC (PDB ID: 7NYC). To generate the composite 2C9-sMAC model we merged models derived from the C5b-focus refined map and those derived from the C9-focus refined map with remaining domains of complement proteins. The composite model was then refined into the full 2C9-sMAC map (EMD-12651), focusing on interaction interfaces between protein chains. Here the whole of the terminal C9 (C9₂) was stabilized with adaptive distance restraints and not refined as the density for this chain was of poorer quality in the full 2C9-sMAC map. To build the 3C9-sMAC model, C9₁ from 2C9-sMAC was duplicated and fitted in the C9₁ and C9₂ positions of 3C9-sMAC, while the terminal C9 from 2C9-sMAC was placed in the last position of the 3C9-sMAC arc (C9₃) in ChimeraX. All other sMAC components were then

added and the composite model was refined in the 3C9-sMAC map (EMD-12560) using ISOLDE, with secondary structure geometries restraints and ligand position restraints applied. Again, adaptive distance restraints were imposed for the C5b:C345C domain. In both 2C9- and 3C9-sMAC models, side chains of the C345C domain were removed as the resolution did not permit confident refinement of their positions. In addition, side chains from other places across the model were punctually removed after refinement where density was lacking. N-linked glycans were built using the Carbohydrate tool in Coot. For C-linked and O-linked glycans, the sugars were fitted in the density from the Coot monomer library and linked to the protein chain using the Acedrg tool ⁵⁴. Glycans and linked side chains were then real-space refined in Coot. Finally, local B-factors of the composite models were refined in REFMAC5 ⁵⁵ using the local resolution filtered map from Relion. Map-Model FSC and the overall quality of the models were assessed in the full 2C9- and 3C9-sMAC maps using the cryoEM validation tools in Phenix ⁵⁶ and MolProbity ⁵⁷.

Map visualization and analysis

Density maps and models were visualized in ChimeraX. Local resolution of the maps and angular distribution of the particles were assessed in Relion and visualized in ChimeraX. Coulombic electrostatic potentials of interaction interfaces were calculated and visualized in ChimeraX. Interaction interfaces and structural rearrangements of complement proteins were analyzed in Coot and ChimeraX. RMSD values between structures of C5b6 were calculated in PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. Figures were generated in ChimeraX, PyMOL and DataGraph.

Bottom-up LC-MS/MS analysis of sMAC

464 For bottom-up LC-MS/MS analysis, purified sMAC (Complement Technologies) in PBS
 465 buffer (10 mM sodium phosphate, 145 mM NaCl, pH 7.3) at a concentration of 1 mg/ml
 466 were introduced into the digestion buffer containing 100 mM Tris-HCl (pH 8.5), 1% w/v
 467 sodium deoxycholate (SDC), 5 mM Tris (2-carboxyethyl) phosphine hydrochloride
 468 (TCEP) and 30 mM chloroacetamide (CAA). Proteins were digested overnight with trypsin
 469 at an enzyme-to-protein-ratio of 1:100 (w/w) at 37 °C. After, the SDC was precipitated by
 470 bringing the sample to 1% trifluoroacetic acid (TFA). The supernatant was collected for
 471 subsequent desalting by an Oasis μ Elution HLB 96-well plate (Waters) positioned on a
 472 vacuum manifold. The desalted proteolytic digest was dried with a SpeedVac apparatus
 473 and stored at -20°C. Prior LC-MS/MS analysis, the sample was reconstituted in 2% formic
 474 acid (FA). Approximately 300 fmol of peptides was separated and analyzed using the
 475 HPLC system (Agilent Technologies) coupled on-line to an Orbitrap Fusion Lumos mass
 476 spectrometer (Thermo Fisher Scientific). The peptides were first trapped on a 100 μ m $\times$
 477 20 mm trap column (in-house packed with ReproSil-Pur C18-AQ, 3 μ m) (Dr. Maisch
 478 GmbH, Ammerbuch-Entringen, Germany) and then separated on the in-tandem
 479 connected 50 μ m $\times$ 500 mm analytical column (in-house packed with Poroshell 120 EC-
 480 C18, 2.7 μ m) (Agilent Technologies). Mobile-phase solvent A consisted of 0.1% FA in
 481 water, and mobile-phase solvent B consisted of 0.1% FA in acetonitrile (ACN). The flow
 482 rate was set to 300 nL/min. A 90 min gradient was used as follows: 0-5 min, 100% solvent
 483 A; 13-44% solvent B within 65 min; 44-100% solvent B within 3 min; 100% solvent B for
 484 5 min; 100% solvent A for 12 min. The mass spectrometer was operated in positive ion
 485 mode, and the spectra were acquired in the data-dependent acquisition mode. A
 486 Nanospray was achieved using a coated fused silica emitter (New Objective) (outer

diameter, 360 μm ; inner diameter, 20 μm ; tip inner diameter, 10 μm) biased to 2 kV. For the MS scans, the mass range was set from 350 to 1800 m/z at a resolution of 60,000, maximum injection time 50 ms, and the normalized automatic Gain Control (AGC) target set to 4×10^5 . For the MS/MS measurements, higher-energy collision dissociation (EThcD) with supplementary activation energy of 27% was used. MS/MS scans were performed with fixed first mass 100 m/z . The resolution was set to 30,000; the AGC target was set to 1×10^5 the precursor isolation width was 1.6 Da and the maximum injection time was set to 250 ms. The LC-MS/MS data were searched against the UniProtKB/Swiss-Prot human proteome sequence database with MaxQuant software (version 1.5.3.30)⁵⁸ with the standard settings and trypsin as digestion enzyme. For label-free quantification intensity based absolute quantification (iBAQ) values were selected as output.

Cross-linking

Purified sMAC (10 μg , Complement Technologies) was cross-linked using 0-2 mM DSS or 0-20 mM DMTMM for 30 min at RT, followed by quenching using a final concentration of 50 mM Tris. Cross-linked samples were analyzed by SDS-PAGE and blue native-PAGE (BN-PAGE) to determine an optimal cross-linker to protein ratio. The optimal DSS and DMTMM concentration (1 mM and 15 mM, Supplementary Fig. 4) was used for cross-linking of 20 μg sMAC (0.5 mg/ml) in triplicates. After quenching the reactions, protein precipitation was performed by adding three times 55 μl cold acetone and subsequent incubation at -20 $^{\circ}\text{C}$ overnight. Precipitated samples were centrifuged at 12,000 $\times g$ for 20 min. After careful removal of the supernatant, the remaining pellet was air-dried until no acetone solution was visible anymore. Pellets were resuspended in 50 μl ammonium

bicarbonate with 0.33 µg trypsin (1:60) and incubated with shaking for 4 h at 37 °C. The solubilized pellets were reduced by 5 mM TCEP for 5 min at 95 °C followed by alkylation with 30 mM CAA for 30 min at 37 °C. Digestion was performed overnight by 0.4 µg trypsin (1:50) at 37 °C. The samples were deglycosylated using PNGase F (1 unit/10 µg) for 3 h at 37 °C. Next, the samples were acidified with TFA before desalting using an Oasis HLB plate (Waters, Wexford, Ireland). Finally, the eluent was dried completely and solubilized in 2% FA before LC-MS/MS-analysis.

LC-MS/MS analysis of cross-linked sMAC

Data was acquired using an Ultimate 3000 system (Thermo Scientific) coupled on-line to an Orbitrap Fusion (Thermo Scientific). First, peptides were trapped using a 0.3x5 mm PepMap-100 C18 pre-column (Thermo Scientific) of 5 µm particle size and 100 Å pore size prior to separation on an analytical column (50 cm of length, 75 µm inner diameter; packed in-house with Poroshell 120 EC-C18, 2.7 µm). Trapping of peptides was performed for 5 min in 9% solvent B (0.1 % FA in 80 % v/v ACN) at a flow rate of 0.005 ml/min. The peptides were subsequently separated as follows: 9-13 % solvent B in 1 min, 13-44 % in 70 min, 44-99 % in 3 min and finally 99 % for 4 min. The flow was 300 nl/min. The mass spectrometer was operated in a data-dependent mode. Full-scan MS spectra from 350-1800 Th were acquired in the Orbitrap at a resolution of 120,000 with the AGC target set to 1×10^6 and maximum injection time of 100 ms. In-source fragmentation was turned on and set to 15 eV. Cycle time for MS² fragmentation scans was set to 2 s. Only peptides with charge states 3-8 were fragmented, and dynamic exclusion properties were set to n = 1, for a duration of 20 s. Fragmentation was performed using in a stepped HCD collision energy mode (27, 30, 33 %) in the ion trap and acquired in the Orbitrap at a

resolution of 50,000 after accumulating a target value of 1×10^5 with an isolation window of 1.4 Th and maximum injection time of 180 ms.

Data analysis of XL-MS

The raw data was first searched using MaxQuant (version 1.6.10.0) to generate a database for the cross-linking search. The signal peptides of the sMAC components were removed. Next, the raw data was searched using pLink (version 2.3.9)⁵⁹ using the conventional cross-linking flow type and DSS or DMTMM as cross-linker. Trypsin was set as a digestion enzyme with two missed cleavages. The peptide mass was 600-6000 Da and peptide length 6-60 amino acids. Carbamidomethyl (C) was set as fixed modification and oxidation (M), hex (W), sulfo (Y), and acetyl (protein N-term) as variable modifications. Precursor, fragment, and filter tolerance were set to 10 ppm and FDR 5% at the PSM level. Cross-linked and loop-linked sites identified in all triplicates were selected for further analysis (DSS: 319 XL, DMTMM: 221 XL, Source data file). The cross-links were mapped on the sMAC structures using PyMOL to obtain C α -C α distances. Distance restraints were set to <20 Å for DMTMM and <30 Å for DSS cross-links. The circos plots were generated in R and only cross-links involving the complement components C5, C6, C7, C8 α , C8 β , C8 γ and C9 were included.

Mass photometry

Mass photometry data was collected on a Refeyn One^{MP} instrument. The instrument was calibrated with a protein standard (made in-house). The following masses were used to generate a standard calibration curve: 73, 149, 479, and 800 kDa. Borosilicate coverslips were extensively cleaned with Milli-Q water and isopropanol prior to the measurements.

sMAC (5 μ l) was applied to 10 μ l buffer (10 mM sodium phosphate, 145 mM NaCl, pH 7.3) on a coverslip resulting in a final concentration 13 μ g/ml. Movies were acquired by using Acquire^{MP} software for 6000 seconds with a frame rate of 100 Hz. The particle landing events detected were 5480 (5241 binding and 239 unbinding). All data was processed in Discover^{MP} software. Masses of sMAC complexes were estimated by fitting a Kernel density distribution to the landing events. Gaussian fit to the mass of GroEL from the protein standard (800 kDa) was generated for peak width reference.

Bacterial activation of serum

S. aureus Wood 46 was grown on blood agar plate O.N. at 37°C. Next, bacteria were suspended in 200 μ l PBS of OD 1.5 and washed one time in PBS. The supernatant was removed and the bacterial pellet was incubated with 250 μ l serum for 3 h at 37°C while shaking. The sample was then centrifuged at 13000 rpm for 3 min. The supernatant was collected and the centrifugation step repeated. The supernatant (serum) was then kept on ice and filtered through a 0.22 μ m filter.

SEC separation of serum samples

An Agilent 1290 Infinity HPLC system (Agilent Technologies) consisting of a vacuum degasser, refrigerated autosampler with a 100 μ l injector loop, binary pump, thermostated two-column compartment, auto collection fraction module, and multi-wavelength detector, was used in this study. The dual-column set-up, comprising a tandem YarraTM 4000-YarraTM 3000 (SEC-4000, 300 x 7.8 mm i.d., 3 μ m, 500 Å; SEC-3000, 300 x 7.8 mm i.d., 3 μ m, 290 Å) two-stage set-up. Both columns were purchased from Phenomenex. The columns were cooled to 17°C while the other bays were chilled to 4°C to minimize sample

degradation. The mobile phase buffer consisted of 150 mM AMAC in water and filtered using a 0.22 μm disposable membrane cartridge (Millipore) before use. Approximately 1.25 mg of serum protein (activated and non-activated fresh serum) was injected per run. The proteins were eluted using isocratic flow within 60 min, and the flow rate was set to 500 $\mu\text{L min}^{-1}$. In total, 74 fractions were collected within a 20-42 time window using an automated fraction collector. The chromatograms were monitored at 280 nm.

LC-MS/MS analysis of SEC fractions

We used bottom-up LC-MS/MS analysis to determine SEC elution profile serum proteins. In total, we collected 74 SEC fractions which were digested by trypsin by the same procedure as described for bottom-up LC-MS/MS. Separation of digested protein samples was performed on an Agilent 1290 Infinity HPLC system (Agilent Technologies). Samples were loaded on a 100 $\mu\text{m} \times 20$ mm trap column (in-house packed with ReproSil-Pur C18-AQ, 3 μm) (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) coupled to a 50 $\mu\text{m} \times 500$ mm analytical column (in-house packed with Poroshell 120 EC-C18, 2.7 μm) (Agilent Technologies, Amstelveen). 10 μL of digest from each SEC fraction was used and the amount ~ 0.1 μg of peptides was loaded on the LC column. The LC-MS/MS run time was set to 60 min with a 300 nL/min flow rate. Mobile phases A (water/0.1% formic acid) and B (80% ACN/0.1% formic acid) were used for 66 min gradient elution: 13–44% B for 35 min, and 44–100% B over 8 min. Samples were analyzed on a Thermo Scientific Q Exactive™ HF quadrupole-Orbitrap instrument (Thermo Scientific). Nano-electrospray ionization was achieved using a coated fused silica emitter (New Objective) biased to 2 kV. The mass spectrometer was operated in positive ion mode, and the spectra were acquired in the data-dependent acquisition mode. Full MS scans were acquired with

60,000 resolution (at 200 m/z) and at a scan mass range of 375 to 1600 m/z. The AGC target was set to 3×10^6 with a maximum injection time of 20 ms. Data-dependent MS/MS (dd-MS/MS) scan was acquired at 30,000 resolution (at 200 m/z) and with a mass range of 200 to 2000 m/z. AGC target was set to 1×10^5 with a maximum injection time defined at 50 ms. One μ scan was acquired in both full MS and dd-MS/MS scans. The data-dependent method was set to isolation and fragmentation of the 12 most intense peaks defined in a full MS scan. Parameters for isolation/fragmentation of selected ion peaks were set as follows: isolation width = 1.4 Th, HCD normalized collision energy (NCE) = 27%. The LC-MS/MS data were searched against UniProtKB/Swiss-Prot human proteome sequence database with MaxQuant software (version 1.5.3.30) using the standard settings and trypsin as digestion enzyme. For label-free quantification iBAQ values were selected as output. For profiling of sMAC components in serum, each fraction's iBAQ values were extracted and normalized to the highest intensity.

613 **Modeling of the clusterin core**

Initial clusterin models were generated using trRosetta²⁶ with the clusterin sequence as input (Uniprot P10909). Alignment of the five generated models in PyMOL revealed a common core composed of residues 40-124 and 256-427. The three models with the best RMSD were selected for further modeling and used as input for comparative modeling using Modeller²⁹. The five disulfide bonds were included as restraints for the modeling. The model with the lowest DOPE score was selected as the final model. The core of the model was verified by mapping the clusterin intra-links on the structure using PyMOL to obtain C α -C α distances.

622

623

Fig. 1. sMAC is a complement activation macromolecule with a heterogeneous composition. (a) CryoEM reconstruction (top) and atomic model (bottom) of sMAC that consists of a core complement complex (C5b, C6, C7 and C8 α /C8 β /C8 γ) together with two C9 molecules (C9₁, C9₂). (b) CryoEM reconstruction (top) and atomic model (bottom) of sMAC with the same core complement complex and three molecules of C9 (C9₁, C9₂, C9₃). CryoEM density maps in a and b are colored according to protein composition. Glycans included in the atomic models are shown as surfaces in the ribbon diagrams. (c) sMAC circos plot of identified DMTMM cross-links within and across complement components (C5, C6, C7, C8, and C9). The complement components are cross-linked to the chaperones vitronectin (VTNC) and clusterin (CLUS). Intra-links are shown as orange lines and inter-links are shown as grey lines. (d) Profiling of sMAC components in nonactivated (top) and bacterial activated (bottom) serum. Serum was separated by SEC and the protein abundance (normalized iBAQ values) in each fraction determined by LC-MS/MS. The grey boxes indicate the elution of sMAC components in nonactivated and activated serum.

Fig. 2. Clusterin bridges complement proteins in sMAC through electrostatic interactions.

(a) CryoEM reconstruction of 3C9-sMAC highlighting the region used in subsequent focused refinements (black-dotted lines). Inset shows the map after density subtraction of the core complement complex and refinement of the C9 oligomer. Density is colored according to protein composition, with regions of the map not accounted for by complement proteins in pink. (b) Structural model for the clusterin core with intra-molecular clusterin cross-links derived from XL-MS mapped (black lines). Over-length cross-links are shown as grey lines and known disulfide bonds within clusterin are shown

in yellow. (c) Intermolecular cross-links between clusterin and C8/C9 plotted on the 3C9-sMAC model (white ribbons). Complement protein residues involved in cross-links are shown as spheres colored according to protein composition. Density not corresponding to complement proteins in the focused refined map (pink surface) is overlaid for reference. (d) Coulombic electrostatic potential ranging from -10 (red) to 10 (blue) kcal/(mol-e) calculated from the models for complement proteins in 3C9-sMAC (bottom surface) and the clusterin core (top surface).

Fig. 3. C7 connects conformational changes of the C345C domain with the MG scaffold of C5b. (a) CryoEM reconstruction of 2C9-sMAC highlighting the region used in subsequent focused refinements (black-dotted lines). Inset corresponds to the map resulting after density subtraction of the MACPF-arc and focused refinement on C5b. Density is colored by protein composition. (b) Panels show density from the focused refined map (colored by protein composition) overlaid with the sMAC atomic model (ribbons) at three interaction interfaces between C7 (orange) and C5b (grey). Glycan extending from C5b:Asn₈₉₃ stabilizes a linker between the C-terminal CCP and first FIM

667 domain of C7 (top). C5b:Tryp₅₈₁ locks into a hydrophobic hinge between the CCP1 and
668 CCP2 domains of C7 (middle). Ionic interactions between the first CCP of C7 and the
669 MG1 domain of C5b (bottom). Side-chains of interface residues shown as sticks. (c)
670 Interface between the C8 β LDL domain (purple) and C5b MG scaffold (MG4 and MG5 in
671 grey). Side-chains of interface residues are shown as sticks. (d) C5b within sMAC
672 (ribbons) colored by RMSD with superposed C5b from the C5b6 crystal structure (PDB
673 ID: 4A5W). Red indicates residues with maximal differences. C345C, MG4 and MG5
674 domains of C5b are highlighted. C6 (blue), C8 (pink) and C7 (orange) are shown as semi-
675 transparent surfaces for reference. (e) Superposition of C5b within sMAC (grey) with
676 corresponding residues in the soluble C5b6 complex (cyan) (PDB ID: 4A5W) showing
677 movement of the C345C domain (top panel). Superposition of C5b from sMAC (grey) with
678 the structural homologue C3b (green) from the C3b:Bb:Properdin complex (PDB ID:
679 6RUR). In both panels, alignments were done on the full molecule and C345C domains
680 were cropped for clarity.

Fig. 4. sMAC traps an alternative conformation of C9. (a) Density for the terminal C9 in the 2C9-sMAC reconstruction (EMD-12647). Density corresponding to the CH3 (orange), TMH2 (pink) and TMH1 (blue) regions of the MACPF domain are highlighted. The remainder of C9 is beige. Model for the alternative C9 conformation is overlaid (ribbon).

(b) Ribbon diagrams for three conformations of C9: soluble C9 from the murine crystal structure (PDB ID: 6CXO) left panel, terminal C9 in 2C9-sMAC, and transmembrane conformation of C9 in MAC (PDB ID: 6H03). CH3, TMH1 and TMH2 regions of the MACPF domain are colored as in a. For the MAC conformation, the full length of C9 TMH hairpins are shown in the bottom right panel. (c) Interaction between the penultimate C9 TMH2 β -hairpins (green) with the helical TMH2 of the terminal C9 (pink). Side-chains of interface residues (NAG-Asn₃₉₄ and Arg₃₄₈) are shown as sticks. TMH1 of the terminal C9 (blue) is shown for context. Density for this region is shown as a transparent surface. (d) Superposition of the C9 MACPF from MAC (dark green) and the conformation in the terminal C9 (light green) shows differences in a loop that contains the disease affected residue Pro₁₄₆ (P146S). (e) Cross-links between TMH2 residues (Lys₃₅₄, Lys₃₈₆, Lys₃₄₉, Asp₄₀₃) derived from XL-MS and mapped on the terminal C9 conformation of 2C9-sMAC. Distance lengths: 9 Å (purple), 14 Å (red), 17 Å (blue), 20 Å (yellow) are shown. (f) Schematic showing structural timeline of MACPF pore formation. In the soluble conformation (C9₂, C9₃), the MACPF domain comprises a central kinked β -sheet (grey) and the pore-forming residues within TMH1 (blue) and TMH2 (pink) are helical. Upon binding the leading edge of the oligomer (C9₁), the central β -sheet straightens and two other MACPF regions: CH3 (orange) and a proline loop (green) rotate as TMH1 (blue) is released. The intermediate conformation is stabilized by the interaction between a basic residue on TMH2 (Arg₃₄₈) with a glycan on the β -strands of the preceding monomer (NAG-Asn₃₉₄). This interaction may play a role in positioning TMH2 before the hairpins are sequentially released to propagate the pore.

709

710 **Data Availability**

711 Data supporting the findings of this manuscript are available from the corresponding
712 authors upon reasonable request. A reporting summary for this article is available as a
713 Supplementary Information file. Source data underlying (Fig. 1c, Fig. 2b, Fig. 4e,
714 Supplementary Fig. 3d-f, Supplementary Fig. 4c-f, and Supplementary Fig. 5a-b) are
715 provided as a Source Data file. The accession numbers for EM maps and models of
716 sMAC reported in this paper are EMD-12646, EMD-12647, EMD-12648, EMD-12649,
717 EMD-12650, EMD-12651 and PDB 7NYC, PDB 7NYD. The MS data from this publication
718 have been deposited to the ProteomeXchange partner MassIVE database and assigned
719 the identifier MSV000087092 (**Reviewer account details:** Username:
720 MSV000087092_reviewer; Password: sMAC_Reviewer)

721

722 **Acknowledgements**

723 We thank S. Islam for computational support and P. Simpson for EM support. Initial
724 screening of samples was carried out at Imperial College London Centre for Structural
725 Biology; cryoEM data was collected at Diamond Light Source. We thank Diamond for
726 access and support of the Cryo-EM facilities at the UK national electron bio-imaging
727 centre (eBIC), proposal EM18659, funded by the Wellcome Trust, MRC, and BBSRC. We
728 acknowledge Maartje Ruyken and Suzan Rooijackers (UMCU, Utrecht) for assistance in
729 preparing the serum samples treated with *S. aureus* bacteria. This project has received
730 funding from the European Research Council (ERC) under the European Union's Horizon
731 2020 research and innovation programme (grant agreement No. 864751) to D.B.; E.C. is

supported by the CRUK Convergence Science Centre at Imperial College London (C24523/A26234) and the EPSRC Centre for Doctoral Training: Chemical Biology: Physical Sciences Innovation (EP/L015498/1). M.V.L., V.F. and A.J.R.H. acknowledge support from the Netherlands Organization for Scientific Research (NWO) funding the Netherlands Proteomics Centre through the X-omics Road Map program (project 184.034.019) and the ENW-PPP project 741.018.201, and the EU Horizon 2020 program INFRAIA project Epic-XS (Project 823839). M.V.L. further acknowledges fellowship support from the Independent Research Fund Denmark (Project 9036-00007B).

Author Contributions

A.M. conducted cryoEM work. A.M. and E.C. built and refined atomic models of complement proteins. A.M. and M.V.L. generated structural models for clusterin. M.V.L. and V.F. performed mass spectrometry experiments. A.M., D.B., V.F. and A.J.R.H. conceived the ideas. A.M. and D.B. analyzed cryoEM data. M.V.L., V.F. and A.J.R.H. analyzed mass spectrometry data. D.B. wrote the manuscript. A.M. and M.V.L. generated the figures. All authors assisted with manuscript editing.

Competing Interests Statement

The authors declare that there are no competing interests.

References

- Tomlinson, S., Taylor, P.W., Morgan, B.P. & Luzio, J.P. Killing of gram-negative bacteria by complement. Fractionation of cell membranes after complement C5b-9 deposition on to the surface of *Salmonella minnesota* Re595. *Biochem J* **263**, 505-11 (1989).

- 757 2. Brodsky, R.A. Paroxysmal nocturnal hemoglobinuria. *Blood* **124**, 2804-11 (2014).
- 758 3. Morgan, B.P. & Harris, C.L. Complement, a target for therapy in inflammatory
759 and degenerative diseases. *Nat Rev Drug Discov* **14**, 857-77 (2015).
- 760 4. Farkas, I. et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion
761 channel formation by homologous C5b-8 as well as C5b-9. *J Physiol* **539**, 537-45
762 (2002).
- 763 5. Doorduyn, D.J. et al. Bacterial killing by complement requires direct anchoring of
764 membrane attack complex precursor C5b-7. *PLoS Pathog* **16**, e1008606 (2020).
- 765 6. Suresh, R., Chandrasekaran, P., Sutterwala, F.S. & Mosser, D.M. Complement-
766 mediated 'bystander' damage initiates host NLRP3 inflammasome activation. *J*
767 *Cell Sci* **129**, 1928-39 (2016).
- 768 7. Chiu, Y.Y., Nisihara, R.M., Würzner, R., Kirschfink, M. & de Messias-Reason, I.J.
769 SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian
770 SLE patients. *J Investig Allergol Clin Immunol* **8**, 239-44 (1998).
- 771 8. Mizuno, M. et al. High Levels of Soluble C5b-9 Complex in Dialysis Fluid May
772 Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients. *PLoS One*
773 **12**, e0169111 (2017).
- 774 9. Mezö, B. et al. Validation of Early Increase in Complement Activation Marker
775 sC5b-9 as a Predictive Biomarker for the Development of Thrombotic
776 Microangiopathy After Stem Cell Transplantation. *Front Med (Lausanne)* **7**,
777 569291 (2020).
- 778 10. Lammerts, R.G.M. et al. Urinary Properdin and sC5b-9 Are Independently
779 Associated With Increased Risk for Graft Failure in Renal Transplant Recipients.
780 *Front Immunol* **10**, 2511 (2019).
- 781 11. Zhao, W.T. et al. Diagnostic roles of urinary kidney injury molecule 1 and soluble
782 C5b-9 in acute tubulointerstitial nephritis. *Am J Physiol Renal Physiol* **317**, F584-
783 F592 (2019).
- 784 12. Murphy, B.F., Kirszbaum, L., Walker, I.D. & d'Apice, A.J. SP-40,40, a newly
785 identified normal human serum protein found in the SC5b-9 complex of
786 complement and in the immune deposits in glomerulonephritis. *J Clin Invest* **81**,
787 1858-64 (1988).
- 788 13. Bhakdi, S. & Tranum-Jensen, J. Terminal membrane C5b-9 complex of human
789 complement: transition from an amphiphilic to a hydrophilic state through binding
790 of the S protein from serum. *J Cell Biol* **94**, 755-9 (1982).
- 791 14. Hadders, M.A. et al. Assembly and regulation of the membrane attack complex
792 based on structures of C5b6 and sC5b9. *Cell Rep* **1**, 200-7 (2012).
- 793 15. Serna, M., Giles, J.L., Morgan, B.P. & Bubeck, D. Structural basis of complement
794 membrane attack complex formation. *Nat Commun* **7**, 10587 (2016).
- 795 16. Menny, A. et al. CryoEM reveals how the complement membrane attack complex
796 ruptures lipid bilayers. *Nat Commun* **9**, 5316 (2018).
- 797 17. Spicer, B.A. et al. The first transmembrane region of complement component-9
798 acts as a brake on its self-assembly. *Nat Commun* **9**, 3266 (2018).
- 799 18. Shiota, M. et al. Clusterin is a critical downstream mediator of stress-induced YB-
800 1 transactivation in prostate cancer. *Mol Cancer Res* **9**, 1755-66 (2011).

19. McDonald, J.F. & Nelsestuen, G.L. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. *Biochemistry* **36**, 7464-73 (1997).
20. Beeg, M. et al. Clusterin Binds to A β 1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation. *J Biol Chem* **291**, 6958-66 (2016).
21. DeMattos, R.B. et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. *Neuron* **41**, 193-202 (2004).
22. Roussotte, F.F. et al. Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly. *J Neurosci* **34**, 6537-45 (2014).
23. Preissner, K.P., Podack, E.R. & Müller-Eberhard, H.J. SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules. *Eur J Immunol* **19**, 69-75 (1989).
24. Liang, H.C. et al. Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease. *J Proteome Res* **14**, 5063-76 (2015).
25. Choi-Miura, N.H., Takahashi, Y., Nakano, Y., Tobe, T. & Tomita, M. Identification of the disulfide bonds in human plasma protein SP-40,40 (apolipoprotein-J). *J Biochem* **112**, 557-61 (1992).
26. Yang, J. et al. Improved protein structure prediction using predicted interresidue orientations. *Proc Natl Acad Sci U S A* **117**, 1496-1503 (2020).
27. Hallström, T. et al. CspA from *Borrelia burgdorferi* inhibits the terminal complement pathway. *mBio* **4**(2013).
28. Caesar, J.J., Wallich, R., Kraicz, P., Zipfel, P.F. & Lea, S.M. Further structural insights into the binding of complement factor H by complement regulator-acquiring surface protein 1 (CspA) of *Borrelia burgdorferi*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* **69**, 629-33 (2013).
29. Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. *Curr Protoc Bioinformatics* **54**, 5.6.1-5.6.37 (2016).
30. Pedersen, D.V. et al. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. *Front Immunol* **10**, 2007 (2019).
31. Hadders, M.A., Beringer, D.X. & Gros, P. Structure of C8 α -MACPF reveals mechanism of membrane attack in complement immune defense. *Science* **317**, 1552-4 (2007).
32. Aleshin, A.E. et al. Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). *J Biol Chem* **287**, 10210-22 (2012).
33. Lovelace, L.L., Cooper, C.L., Sodetz, J.M. & Lebiada, L. Structure of human C8 protein provides mechanistic insight into membrane pore formation by complement. *J Biol Chem* **286**, 17585-92 (2011).
34. Kremlitzka, M. et al. Functional analyses of rare genetic variants in complement component C9 identified in patients with age-related macular degeneration. *Hum Mol Genet* (2018).

35. Pang, S.S. et al. The cryo-EM structure of the acid activatable pore-forming immune effector Macrophage-expressed gene 1. *Nat Commun* **10**, 4288 (2019).
36. Law, R.H. et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. *Nature* **468**, 447-51 (2010).
37. Ni, T. et al. Structure and mechanism of bactericidal mammalian perforin-2, an ancient agent of innate immunity. *Sci Adv* **6**, eaax8286 (2020).
38. Tschopp, J., Chonn, A., Hertig, S. & French, L.E. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. *J Immunol* **151**, 2159-65 (1993).
39. Lakins, J.N. et al. Evidence that clusterin has discrete chaperone and ligand binding sites. *Biochemistry* **41**, 282-91 (2002).
40. Endo, Y. et al. Apolipoprotein E and clusterin inhibit the early phase of amyloid- β aggregation in an in vitro model of cerebral amyloid angiopathy. *Acta Neuropathol Commun* **7**, 12 (2019).
41. Matsubara, E., Soto, C., Governale, S., Frangione, B. & Ghiso, J. Apolipoprotein J and Alzheimer's amyloid beta solubility. *Biochem J* **316** (Pt 2), 671-9 (1996).
42. Itakura, E., Chiba, M., Murata, T. & Matsuura, A. Heparan sulfate is a clearance receptor for aberrant extracellular proteins. *J Cell Biol* **219**(2020).
43. Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. *Cell Death Dis* **7**, e2215 (2016).
44. Naydenova, K. & Russo, C.J. Measuring the effects of particle orientation to improve the efficiency of electron cryomicroscopy. *Nat Commun* **8**, 629 (2017).
45. Scheres, S.H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J Struct Biol* **180**, 519-30 (2012).
46. Rohou, A. & Grigorieff, N. CTFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* **192**, 216-21 (2015).
47. Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. *Commun Biol* **2**, 218 (2019).
48. Zivanov, J., Nakane, T. & Scheres, S.H.W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in. *IUCrJ* **7**, 253-267 (2020).
49. Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. *bioRxiv*, 2020.06.12.148296 (2020).
50. Phelan, M.M. et al. Solution structure of factor I-like modules from complement C7 reveals a pair of follistatin domains in compact pseudosymmetric arrangement. *J Biol Chem* **284**, 19637-49 (2009).
51. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).
52. Croll, T.I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr D Struct Biol* **74**, 519-530 (2018).
53. Pettersen, E.F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci* **30**, 70-82 (2021).
54. Long, F. et al. AceDRG: a stereochemical description generator for ligands. *Acta Crystallogr D Struct Biol* **73**, 112-122 (2017).

55. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallogr* **67**, 355-67 (2011).
56. Afonine, P.V. et al. New tools for the analysis and validation of cryo-EM maps and atomic models. *Acta Crystallogr D Struct Biol* **74**, 814-840 (2018).
57. Williams, C.J. et al. MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci* **27**, 293-315 (2018).
58. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* **26**, 1367-72 (2008).
59. Chen, Z.L. et al. A high-speed search engine pLink 2 with systematic evaluation for proteome-scale identification of cross-linked peptides. *Nat Commun* **10**, 3404 (2019).